Swiss Deal Ledger Pharma & life sciences

Novartis → Avidity Biosciences

Novartis acquired Avidity Biosciences, a US biotech developing RNA-based therapies for neuromuscular diseases.

Announced October 2025OutboundCompleted

  • c. USD 12bnValue as disclosed
  • CompletedCompleted February 2026
  • OutboundSwiss buyer, foreign target
  • Oct 2025Announced

The record

One line of the Swiss Deal Ledger
BuyerNovartis
TargetAvidity Biosciences
SectorPharma & life sciences
DirectionOutbound (swiss buyer, foreign target)
Valuec. USD 12bn
AnnouncedOctober 2025
StatusCompleted
DetailCompleted February 2026
SourceNovartis

Spotted a change on this deal? research@valstron.ch

The Valstron Brief

New Deal Snapshots, delivered.

Every new Snapshot and selected perspectives, on the day they are published.